Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David

Nectin Therapeutics is developing a number of antibodies that can enhance the treatments being offered to cancer patients. Jerusalem immuno-oncology biotherapies company Nectin Therapeutics has

Reltecimod is Atox Bio‘s lead product in development and is currently in late stage clinical trials for Necrotizing Soft Tissue Infections (NSTI) (Flesh Eating Disease)

Immunovative Therapies‘ universal vaccine is designed to protect elderly adults from all respiratory viral infections, including COVID-19, influenza and any future mutations or novel viral

The NIAID of the NIH completed the Clinical Study Report (CSR) of a Phase 2 clinical trial of the BiondVax’s M-001 universal influenza vaccine candidate.

The funding award to Betalin Therapeutics along with their partners from Dresden and Zurich was just announced. The demand for diabetes drugs keeps increasing as

On April 22nd, Silkim Pharma filed a pre-Investigational New Drug (PIND) meeting request with the U.S. Food and Drug Administration (FDA) for its drug candidate

NANO-X IMAGING LTD, an innovative medical-imaging technology company, announces today a partnership agreement with the Hadassah Hospital in Jerusalem, to use the new Nanox ARC